Boston Scientific completes Valencia Technologies acquisition to broaden urology portfolio

US medical device giant Boston Scientific has finalised its takeover of Valencia Technologies, a company specialising in neuromodulation devices for the treatment of bladder dysfunction, in a move that further consolidates its position in the urology sector.

According to Modern Healthcare, the acquisition adds a targeted neuromodulation platform to Boston Scientific's existing urology offering, extending the company's capabilities in a segment where demand for minimally invasive interventions continues to grow.

The Valencia Technologies deal is the latest in a sustained period of expansion for the Massachusetts-headquartered firm. In January, Boston Scientific announced an agreement to acquire Penumbra Inc., a maker of devices for the treatment of brain and vascular conditions, in a transaction valued at more than $14 billion (€12.0 billion). That same month, it closed its acquisition of Nalu Medical Inc., a chronic pain neuromodulation device company, in a deal worth $533 million (€456 million) that had been announced the previous October.

The acquisitions reflect a broader strategic pattern within the medical device industry, where established players are using inorganic growth to rapidly extend their reach across adjacent therapeutic areas. Neuromodulation — encompassing devices that modulate nerve activity to treat conditions ranging from chronic pain to urinary disorders — has become a particularly active area of corporate dealmaking.

No financial terms were disclosed for the Valencia Technologies transaction.

Boston Scientific's urology division already encompasses a broad range of products addressing conditions including kidney stones, benign prostatic hyperplasia and incontinence. The addition of Valencia Technologies' bladder-focused neuromodulation technology is expected to deepen that clinical breadth further.

The deal underscores growing private healthcare sector interest in device-based alternatives to pharmaceutical management of chronic conditions, particularly those affecting quality of life in ageing patient populations.

Get the full picture on this acquisition by reading the complete report.